Generic Name and Formulations:
Cytomegalovirus immune globulin (human) 50mg/mL; soln for IV infusion; preservative-free; contains sucrose.
CSL Behring, LLC
Indications for CYTOGAM:
For the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.
Kidney transplant: 150mg/kg within 72hrs of transplant, then 100mg/kg at 2 weeks, 4 weeks, 6 weeks, and 8 weeks post transplant, then 50mg/kg 12 weeks and 16 weeks post transplant. Liver, pancreas, lung, heart: 150mg/kg within 72hrs of transplant, then 150mg/kg 2 weeks, 4 weeks, 6 weeks. and 8 weeks post transplant, then 100mg/kg 12 weeks and 16 weeks post transplant. Initial dose: 15mg/kg/hr; if no adverse reactions after 30 minutes, may increase to 30mg/kg/hr; if no reactions after another 30 minutes, may increase to max 60mg/kg/hr (volume not to exceed 75mL/hr). Subsequent doses: 15mg/kg/hr for 15 minutes; if no reaction, increase to 30mg/kg/hr for 15 minutes and then to max rate of 60mg/kg/hr.
Selective immunoglobulin A deficiency.
Renal insufficiency, diabetes, >65yrs, volume depletion, sepsis, paraproteinemia: increased risk of renal dysfunction or acute renal failure; monitor urine output, BUN, serum creatinine before and during treatment; consider discontinuing if renal function deteriorates. Correct hypovolemia before starting treatment. Contains human plasma; monitor for possible infection transmission. Cardiovascular disease. Coagulation disorders. Immobilized for long periods. Hyperviscosity (perform baseline assessment of blood viscosity). Monitor for hemolysis and hemolytic anemia. Monitor for pulmonary dysfunction; perform test for anti-neutrophil antibodies if transfusion-related acute lung injury (TRALI) suspected. Have epinephrine inj and diphenhydramine available; discontinue if hypotension or anaphylaxis occurs. Elderly. Neonates. Infants. Pregnancy (Cat.C).
Avoid live viral vaccines. Concomitant nephrotoxic drugs: increased risk of acute renal failure.
Flushing, chills, muscle cramps, back pain, fever, GI upset, arthralgia, wheezing; renal dysfunction (may be fatal); rare: hemolytic anemia, aseptic meningitis syndrome (esp. high dose of 2g/kg), TRALI, thrombosis.
Single-dose vial (50mL)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|